(Photo Courtesy: www.d3eksha.com)
The company's latest report states that this increase, which will occur across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, will be driven primarily by the launch from 2017 of the first biologic for the treatment of moderate to severe disease, namely Sanofi/Regeneron's dupilumab.
Other key growth drivers in the atopic dermatitis space will be the continued uptake of topical calcineurin inhibitors, and the increased use of systemic therapies.
The off-label use of Novartis' Xolair is also expected to increase, albeit at a slower rate towards the end of the forecast period.
However, Dr Abhilok Garg, GlobalData's Analyst covering Immunology, says dupilumab's launch across the 7MM will be the most pertinent event that could alter the competitive landscape over the mid-to-late forecast period, as the drug is expected to contribute an estimated $3.8 billion to global sales by 2024.
Dr Garg explains: "The excitement surrounding dupilumab stems from its novelty as an anti-IL-4R inhibitor, and its promising clinical trial data to date. It also has the potential to displace cyclosporine, which is the current gold-standard systemic agent, but has undesirable side effects that limit its long-term use.